313 related articles for article (PubMed ID: 35478418)
21. Early B-cell factors involve in the tumorigenesis and predict the overall survival of gastric cancer.
Wang Q; Liang J; Hu X; Gu S; Xu Q; Yan J
Biosci Rep; 2021 Jul; 41(7):. PubMed ID: 34100918
[TBL] [Abstract][Full Text] [Related]
22. Genomic and transcriptomic profiling indicates the prognosis significance of mutational signature for TMB-high subtype in Chinese patients with gastric cancer.
Cheng Y; Bu D; Zhang Q; Sun R; Lyle S; Zhao G; Dong L; Li H; Zhao Y; Yu J; Hao X
J Adv Res; 2023 Sep; 51():121-134. PubMed ID: 36351537
[TBL] [Abstract][Full Text] [Related]
23. Identification of novel biomarkers, MUC5AC, MUC1, KRT7, GAPDH, CD44 for gastric cancer.
Yang J
Med Oncol; 2020 Mar; 37(5):34. PubMed ID: 32219571
[TBL] [Abstract][Full Text] [Related]
24. Computed tomography-detected extramural venous invasion-related gene signature: a potential negative biomarker of immune checkpoint inhibitor treatment in patients with gastric cancer.
Yang H; Gou X; Feng C; Zhang Y; Chai F; Hong N; Ye Y; Wang Y; Gao B; Cheng J
J Transl Med; 2023 Jan; 21(1):4. PubMed ID: 36604653
[TBL] [Abstract][Full Text] [Related]
25. Pan-cancer analysis of N4-acetylcytidine adaptor THUMPD1 as a predictor for prognosis and immunotherapy.
Li K; Liu J; Yang X; Tu Z; Huang K; Zhu X
Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34762107
[TBL] [Abstract][Full Text] [Related]
26. CLEC11A expression as a prognostic biomarker in correlation to immune cells of gastric cancer.
Fang W; Wan D; Yu Y; Zhang L
Biomol Biomed; 2024 Jan; 24(1):101-124. PubMed ID: 37597212
[TBL] [Abstract][Full Text] [Related]
27. The association of sex-biased ATRX mutation in female gastric cancer patients with enhanced immunotherapy-related anticancer immunity.
Ge Y; Wei F; Du G; Fei G; Li W; Li X; Chu J; Wei P
BMC Cancer; 2021 Mar; 21(1):240. PubMed ID: 33678158
[TBL] [Abstract][Full Text] [Related]
28. Analyzing the expression and clinical significance of CENPE in gastric cancer.
Wang J; Li X; Qiang X; Yin X; Guo L
BMC Med Genomics; 2024 May; 17(1):119. PubMed ID: 38702677
[TBL] [Abstract][Full Text] [Related]
29. A systematic analysis of
Jiang Y; Wang X; Li L; He J; Jin Q; Long D; Liu C; Zhou W; Liu K
Front Genet; 2022; 13():926943. PubMed ID: 35991552
[No Abstract] [Full Text] [Related]
30.
Xiao Y; Zhang H; Du G; Meng X; Wu T; Zhou Q; Wang Y; Tan B
Technol Cancer Res Treat; 2020; 19():1533033820970684. PubMed ID: 33176601
[TBL] [Abstract][Full Text] [Related]
31. Identification of lactylation related model to predict prognostic, tumor infiltrating immunocytes and response of immunotherapy in gastric cancer.
Yang H; Zou X; Yang S; Zhang A; Li N; Ma Z
Front Immunol; 2023; 14():1149989. PubMed ID: 36936929
[TBL] [Abstract][Full Text] [Related]
32. Prognostic and Immunological Value of GNB4 in Gastric Cancer by Analyzing TCGA Database.
Liu B; Chen L; Huang H; Huang H; Jin H; Fu C
Dis Markers; 2022; 2022():7803642. PubMed ID: 35756485
[TBL] [Abstract][Full Text] [Related]
33. Development and verification of an immune-related gene prognostic index for gastric cancer.
Zhang C; Liu T; Wang J; Zhang J
Sci Rep; 2022 Sep; 12(1):15693. PubMed ID: 36127384
[TBL] [Abstract][Full Text] [Related]
34. A pan-cancer analysis revealing the role of TIGIT in tumor microenvironment.
Wen J; Mao X; Cheng Q; Liu Z; Liu F
Sci Rep; 2021 Nov; 11(1):22502. PubMed ID: 34795387
[TBL] [Abstract][Full Text] [Related]
35. POC1A, prognostic biomarker of immunosuppressive microenvironment in cancer.
Zhao Q; Gao S; Chen X; Zhu X
Aging (Albany NY); 2022 Jun; 14(12):5195-5210. PubMed ID: 35748773
[TBL] [Abstract][Full Text] [Related]
36. PTBPs: An immunomodulatory-related prognostic biomarker in pan-cancer.
Chen C; Shang A; Gao Y; Huang J; Liu G; Cho WC; Li D
Front Mol Biosci; 2022; 9():968458. PubMed ID: 36203873
[No Abstract] [Full Text] [Related]
37. BICC1 as a novel prognostic biomarker in gastric cancer correlating with immune infiltrates.
Zhao R; Peng C; Song C; Zhao Q; Rong J; Wang H; Ding W; Wang F; Xie Y
Int Immunopharmacol; 2020 Oct; 87():106828. PubMed ID: 32736193
[TBL] [Abstract][Full Text] [Related]
38. Characterization of SHCBP1 to prognosis and immunological landscape in pan-cancer: novel insights to biomarker and therapeutic targets.
Jiang F; Shi Y; Wang Y; Ge C; Zhu J; Fang H; Zhang Y; Zhang Y; Jian H; Lei T; Lan S; Cao L; Yu H; Fang D
Aging (Albany NY); 2023 Mar; 15(6):2066-2081. PubMed ID: 36920183
[TBL] [Abstract][Full Text] [Related]
39. Cytolytic activity score as a biomarker for antitumor immunity and clinical outcome in patients with gastric cancer.
Hu Q; Nonaka K; Wakiyama H; Miyashita Y; Fujimoto Y; Jogo T; Hokonohara K; Nakanishi R; Hisamatsu Y; Ando K; Kimura Y; Masuda T; Oki E; Mimori K; Oda Y; Mori M
Cancer Med; 2021 May; 10(9):3129-3138. PubMed ID: 33769705
[TBL] [Abstract][Full Text] [Related]
40. A new risk model based on a 11-m
Lei L; Li N; Yuan P; Liu D
BMC Cancer; 2022 Apr; 22(1):365. PubMed ID: 35382776
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
